<DOC>
	<DOCNO>NCT00364013</DOCNO>
	<brief_summary>The purpose study determine treatment effect panitumumab combination FOLFOX compare FOLFOX alone first line therapy metastatic colorectal cancer</brief_summary>
	<brief_title>PRIME : Panitumumab Randomized Trial In Combination With Chemotherapy Metastatic Colorectal Cancer Determine Efficacy</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Man woman least 18 year old Diagnosis metastatic colorectal cancer At least 1 unidimensionally measurable lesion least 20 mm per modify RECIST Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 Paraffinembedded tumor tissue primary tumor metastasis available central analyse History know presence central nervous system ( CNS ) metastases History another primary cancer , except : Curatively treat situ cervical cancer , Curatively resect nonmelanoma skin cancer , Other primary solid tumor curatively treat know active disease present treatment administer â‰¥ 5 year randomization Prior chemotherapy systemic therapy treatment metastatic colorectal carcinoma except : adjuvant fluoropyrimidinebased chemotherapy prior fluoropyrimidine therapy administer solely purpose radiosensitization Prior oxaliplatin therapy Prior antiepidermal growth factor receptor ( EGFr ) antibody therapy ( eg , cetuximab ) treatment small molecule EGFr inhibitor ( eg , erlotinib ) Clinically significant cardiovascular disease ( include myocardial infarction , unstable angina , symptomatic congestive heart failure , serious uncontrolled cardiac arrhythmia ) 1 year prior randomization History interstitial lung disease ( eg , pneumonitis pulmonary fibrosis ) evidence interstitial lung disease baseline chest compute tomography ( CT ) scan Active inflammatory bowel disease bowel disease cause chronic diarrhea ( defined &gt; Common terminology criterion ( CTC ) grade 2 [ CTCAE version 3.0 ] ) Peripheral sensory neuropathy functional impairment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Oncology</keyword>
	<keyword>Cancer</keyword>
	<keyword>metastatic colorectal cancer</keyword>
	<keyword>EGFr</keyword>
	<keyword>Panitumumab</keyword>
	<keyword>Clinical Trail</keyword>
	<keyword>Amgen</keyword>
</DOC>